NCT00812175View on ClinicalTrials.gov

Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib

CompletedOBSERVATIONAL
Enrollment

3,371

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions
Carcinoma, Hepatocellular
Interventions
DRUG

Sorafenib (Nexavar, BAY43-9006)

Systemic oral therapy according to product information

Trial Locations (75)

Unknown

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY